Data compiled by Redley Lamar · ChainSifter Intelligence
9Suppliers
2Customers
3Debt Items
6Related Chains
Source-Backed Evidence Depth
Cardiff Oncology, Inc. (CRDF) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
15Total relationships
5Distinct source URLs
13High confidence
0.876Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Cardiff Oncology, Inc. Suppliers
Ticker
Name
Confidence
Evidence
CLINICAL-RESEARCH-ORGANIZATIONS
CLINICAL-RESEARCH-ORGANIZATIONS
92%
The Company accrues costs for clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the Clinical Research Organizations…
INVESTIGATORS
INVESTIGATORS
92%
The Company accrues costs for clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the Clinical Research Organizations…
NERVIANO
NERVIANO
92%
In March 2017, the Company entered into a license agreement with Nerviano which granted the Company development and commercialization rights to NMS-1286937, which the Company refers to as onvansertib.
PROFESSIONAL-SERVICE-PROVIDERS
PROFESSIONAL-SERVICE-PROVIDERS
92%
The Company accrues costs for clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the Clinical Research Organizations…
NERVIANO-MEDICAL-SCIENCES-S-R-L
NERVIANO-MEDICAL-SCIENCES-S-R-L
90%
the Company was informed in writing by NMS that NMS was terminating the Agreement pursuant to Section 11.3 of the Agreement
PFIZER-IGNITE
PFIZER-IGNITE
90%
The trial is conducted in partnership with Pfizer Ignite, an end-to-end service for biotech companies.
TROVAGENE-INC
TROVAGENE-INC
85%
10.10 Form of Seventh Amendment to Standard Industrial Net Lease dated April 4, 2016 between Trovagene, Inc. and BMR-Coast 9 LP
Reciprocal relationship from OKYO graph: Reciprocal relationship from CRDF graph: Reciprocal relationship from OKYO graph: oreign currency transactions are translated into the functional currency usi…
Reciprocal relationship from TLSA graph: Reciprocal relationship from CRDF graph: Reciprocal relationship from TLSA graph: Reciprocal relationship from CRDF graph: Reciprocal relationship from TLSA g…
Cardiff Oncology, Inc. Customers
Ticker
Name
Confidence
Evidence
PFIZER-INC
PFIZER-INC
92%
10.14 @ Development Agreement between Cardiff Oncology, Inc. and Pfizer, Inc. dated June 30, 2023
PFIZER-IGNITE
PFIZER-IGNITE
85%
The trial is conducted in partnership with Pfizer Ignite, an end-to-end service for biotech companies.
Cardiff Oncology, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
CRDF-DEBT-8843
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2022-12-31.
CRDF-DEBT
Debt stack $646,000
90%
Market cache reports total debt of $646,000.
CRDF-DEBT-8842
Warrants outstanding: 2213115
90%
xbrl warrant detail from xbrl 2025-12-31.
Cardiff Oncology, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Cardiff Oncology, Inc..
Cardiff Oncology, Inc. Ownership
Holder
Name
Confidence
Evidence
CRDF-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 116 tracked holders.
Cardiff Oncology, Inc. Extended Supply Chain Network
